Orion to hand over exclusive rights to MSD for prostate cancer therapy
License out/inPhase 3Clinical Trial TerminationPhase 2
Preview
Source: Pharmaceutical Technology
The non-steroidal, selective CYP11A1 inhibitorCYP11A1 inhibitor opevesostat is being studied in two pivotal Phase III trials, OMAHA1 and OMAHA2. Credits: Tada Images/Shutterstock.com
Merck & Co (MSD) has announced that its ongoing agreement with Orion Corporation for the co-development and co-commercialisation of opevesostat (MK-5684/ODM-208) has changed to give MSD exclusive rights to the investigational hormone-dependent cancer treatment.
Under the terms of the original agreement, both MSD and Orion had the option to convert the licensing agreement into an exclusive global license for MSD. A wholly exclusive license agreement would give MSD exclusive rights for the global development and commercialisation of opevesostat and other CYP11A1 inhibitorCYP11A1 inhibitor-targeting candidates. Consequently, Orion is now in a position to receive up to $30m for developmental milestones, up to $625m for regulatory milestones, and up to $975m for sales-contingent milestones.
Changing the agreement with MSD allows Orion to allocate its resources to advance other projects while maximising the potential of opevesostat for the treatment of certain prostate cancers and reaping the developmental and commercial benefits of the candidate, Orion president and CEO, Liisa Hurme said in the 1 July press release.
Espoo, Finland-based Orion will also continue to be responsible for the drug manufacturing for the clinical and commercial supply for MSD.
Opevesostat, a non-steroidal, selective CYP11A1 inhibitorCYP11A1 inhibitor, is designed to suppress the production of steroid hormones that may induce the androgen receptor signalling pathway activated in hormone-dependent cancers such as prostate cancer. The treatment is actively being evaluated in two pivotal Phase III studies, OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650).
See Also:Eisai and Bristol Myers Squibb terminate ADC development deal
Preview
Source: Pharmaceutical Technology
Orion to hand over exclusive rights to MSD for prostate cancer therapy
Preview
Source: Pharmaceutical Technology
According to GlobalData’s consensus forecasts, opevesostat is expected to generate global sales of $207m in 2030. GlobalData is the parent company of Pharmaceutical Technology.
The randomised, open-label OMAHA1 compares the opevesostat/hormone replacement therapy (HRT) combination therapy to an alternative next-generation hormonal agent (NHA) like abiraterone acetate or enzalutamide. The study is recruiting patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed a prior line of NHAs or two prior taxanes. Johnson and Johnson markets abiraterone as Zytiga while enzalutamide is sold as Xtandi by Pfizer and Astellas Oncology. The primary endpoints of this study are overall survival and radiographic progression-free survival (rPFS) in androgen receptor ligand-binding domain (AR LBD) mutation status patients.
Earlier this year, MSD signed a clinical trial collaboration and supply agreement with Lava Therapeutics to study Lava’s prostate cancer therapy, LAVA-1207, as a potential combination treatment with the former’s blockbuster drug Keytruda (pembrolizumab).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.